Clinical Research Directory
Browse clinical research sites, groups, and studies.
Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin (Hi-DoRi-3)
Sponsor: Seoul National University Hospital
Summary
The purpose of this study is to investigate the effectiveness and safety of the regimen including high dose rifampicin for individualized duration (3 months after Culture Conversion) for the treatment of drug-sensitive pulmonary tuberculosis.
Official title: Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin to 3 Months After Culture Conversion (Hi-DoRi-3): A Phase 3, Multicenter, Randomized, Open-label, Clinical Trial
Key Details
Gender
All
Age Range
19 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
926
Start Date
2020-09
Completion Date
2026-12
Last Updated
2020-07-24
Healthy Volunteers
No
Conditions
Interventions
High-dose rifampicin
30mg/kg
Isoniazid
300mg
Pyrazinamide
20-30mg/kg
Ethambutol
15-20mg/kg
Rifampicin
10mg/kg
Locations (1)
Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine and Lung Institute of Medical Research Center, Seoul National University College of Medicine
Seoul, South Korea